Agilon Health, Inc. (NYSE:AGL) Receives Average Recommendation of “Hold” from Analysts

Agilon Health, Inc. (NYSE:AGL) has been given a consensus rating of “Hold” by the fifteen research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $58.7273.

A number of brokerages have issued reports on AGL. Robert W. Baird upped their target price on Agilon Health from $20.00 to $35.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Citigroup reiterated a “neutral” rating and set a $80.00 target price (up from $18.75) on shares of Agilon Health in a research report on Friday, May 15th. Barclays upgraded shares of Agilon Health from an “underweight” rating to an “equal weight” rating and set a $81.00 price target for the company in a research report on Tuesday, May 26th. Wells Fargo & Company restated an “overweight” rating and issued a $72.00 price objective (up from $37.50) on shares of Agilon Health in a report on Friday, May 8th. Finally, Jefferies Financial Group upgraded Agilon Health from a “hold” rating to a “buy” rating and upped their price target for the company from $27.50 to $48.00 in a research report on Thursday, May 7th.

Agilon Health Price Performance

Shares of NYSE AGL opened at $104.60 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.08. The firm has a market cap of $1.74 billion, a PE ratio of -4.70 and a beta of 3.02. Agilon Health has a 1-year low of $7.48 and a 1-year high of $104.55. The company has a fifty day moving average price of $51.08 and a 200 day moving average price of $28.77.

Agilon Health (NYSE:AGL) last announced its earnings results on Wednesday, May 6th. The company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.04 by $0.76. The business had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.38 billion. Agilon Health had a negative net margin of 6.09% and a negative return on equity of 146.03%. Research analysts predict that Agilon Health will post -3.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilon Health

Several institutional investors and hedge funds have recently made changes to their positions in the business. Alpine Global Management LLC bought a new position in shares of Agilon Health during the 4th quarter worth approximately $84,000. Invesco Ltd. lifted its holdings in shares of Agilon Health by 30.7% in the 4th quarter. Invesco Ltd. now owns 1,004,266 shares of the company’s stock worth $692,000 after purchasing an additional 235,951 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Agilon Health during the 4th quarter valued at $86,000. Numerai GP LLC raised its holdings in Agilon Health by 207.3% during the fourth quarter. Numerai GP LLC now owns 1,228,071 shares of the company’s stock worth $846,000 after buying an additional 828,472 shares during the last quarter. Finally, Odyssean LLC acquired a new position in shares of Agilon Health during the fourth quarter valued at about $96,000.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.